NASDAQ:BTTX Better Therapeutics (BTTX) Stock Price, News & Analysis $0.0001 0.00 (0.00%) As of 11/12/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC Filings About Better Therapeutics Stock (NASDAQ:BTTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Better Therapeutics alerts:Sign Up Key Stats Today's Range$0.0001▼$0.000150-Day Range N/A52-Week Range$0.0001▼$0.0002Volume3,801 shsAverage Volume9,489 shsMarket Capitalization$4.06 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Better Therapeutics was a U.S.-based digital health company that developed prescription digital therapeutics for cardiometabolic conditions. Its software-based treatments used principles of cognitive behavioral therapy to help patients make changes to behaviors associated with chronic disease. The company’s lead product, AspyreRx, was authorized by the U.S. Food and Drug Administration in 2023 as a prescription digital therapeutic for adults with type 2 diabetes. Designed for use alongside standard care, the program aimed to help patients improve blood sugar management through structured behavioral therapy delivered digitally. Better Therapeutics later announced that it would wind down its operations. Its business centered on the development of digital treatment programs rather than conventional drugs or medical devices.AI Generated. May Contain Errors. Read More Receive BTTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Better Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BTTX Stock News HeadlinesBetter Therapeutics consensus price target lowered by 71.43% to $1.53November 3, 2026 | msn.comBTTX Better Therapeutics, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comWorse than socialismDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead. | Porter & Company (Ad)Janux Therapeutics Inc (JANX) Receives a Buy from BTIGNovember 7, 2024 | markets.businessinsider.comThis High-Flying Stock Just Became a Better BuyOctober 31, 2024 | fool.comBicara Therapeutics: A Buy Rating on Promising Clinical Progress and Financial FortitudeOctober 9, 2024 | markets.businessinsider.comBetter Therapeutics (OTC:BTTX) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.comViking Therapeutics: Leaping Ahead In The Weight-Loss RaceAugust 22, 2024 | seekingalpha.comSee More Headlines BTTX Stock Analysis - Frequently Asked Questions How have BTTX shares performed this year? Better Therapeutics' stock was trading at $0.0001 at the beginning of 2026. Since then, BTTX stock has increased by 0.0% and is now trading at $0.0001. What other stocks do shareholders of Better Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Better Therapeutics investors own include NIO (NIO), Advanced Micro Devices (AMD), MARA (MARA), Peloton Interactive (PTON), Ginkgo Bioworks (DNA), Ford Motor (F) and Aterian (ATER). Company Calendar Today11/21/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Health services Sub-IndustryHealthcare Current SymbolNASDAQ:BTTX CIK1832415 Webwww.bettertx.com Phone415-887-2311FaxN/AEmployees54Year Founded2015Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares40,580,000Free Float24,233,000Market Cap$4.06 thousand OptionableNo Data Beta0.91 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:BTTX) was last updated on 11/12/2026 by MarketBeat.com Staff. From Our PartnersPrediction: NVDA will “snap back” on this dateOthers paid $500 for the Snapback Indicator. For Black Friday, Base Camp Trading is offering lifetime access f...Base Camp Trading | SponsoredYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | Sponsored“IMPERIUM”: The #1 investment of 2027Could a strange new bio-chip be the most transformative innovation in history? Elon Musk calls it "amazing." A...Banyan Hill Publishing | SponsoredNoah’s Ark found?Scientists may have discovered Noah's Ark buried under a mountain in eastern Turkey, just two miles from the I...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Better Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Better Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.